About Us

Company Overview

Alpheus is a private, clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led, tumor-selective oncology approach designed to activate 5-ALA–derived protoporphyrin IX (PpIX), beginning with glioblastoma. PoMA is designed to enable localized pharmacologic activity through activation of tumor-localized porphyrin metabolites using proprietary low-intensity defocused ultrasound. The company’s lead program is being evaluated in a randomized Phase 2b trial in newly diagnosed glioblastoma.

Leadership

Management Team

Imran Eba


/in /by

Chief Financial Officer

View Bio

Jeremy Ling

/in /by

Chief Technology Officer

View Bio

Ann-Marie Hulstine


/in /by

Vice President, Clinical Operations

View Bio

Mike Preigh, Ph.D

/in /by

Vice President, Chemistry, Manufacturing & Controls (CMC)

View Bio

Nick Ellens, Ph.D

/in /by

Vice President, Research & Development

View Bio

Board of Directors

Scientific Advisory Board

Roger Stupp, MD

/in /by

Chief of Neuro-oncology, Professor of Neurological Surgery, Medicine and Neurology, Feinberg School of Medicine at Northwestern University.

View Bio

Walter Stummer, MD

/in /by

Professor and Chair, Department of Neurosurgery
University Hospital Münster

View Bio

David Reardon, MD

/in /by

Professor, Medicine, Harvard Medical School;
Clinical Director, Center for Neuro-Oncology, Medical Oncology, Dana-Farber Cancer Institute.

View Bio

Investors

Contact us

Corporate

Alpheus Medical, Inc.
1266 Park Road
Chanhassen, MN 55317
info@alpheusmedical.com

Legal

Investigational Use Disclaimer

This therapy is investigational and has not been approved by the U.S. Food and Drug Administration. Safety and efficacy have not been established.

Medical Disclaimer

The information on this website is for informational purposes only and is not intended as medical advice. Patients should always consult qualified healthcare professionals about diagnosis or treatment options.

Forward-Looking Statement

This website may contain forward-looking statements based on current expectations that involve risks and uncertainties. Actual results may differ materially. Nothing on this site constitutes an offer to sell or the solicitation of an offer to buy any securities.

California Declaration of Compliance

Alpheus Medical, Inc. declares that, to the best of its knowledge, it is in compliance with the requirements of California Health & Safety Code §§ 119400–119402 concerning the marketing of pharmaceutical products and has developed a Comprehensive Compliance Program consistent with the U.S. Department of Health and Human Services Office of Inspector General’s Compliance Program Guidance for Pharmaceutical Manufacturers and the PhRMA Code. To request a copy, please contact compliance@alpheusmedical.com.

© 2026 Alpheus Medical, Inc. All rights reserved. Alpheus, LIDU and PoMA are trademarks of Alpheus Medical, Inc.

This site is intended for U.S. audiences only. Privacy Policy | Terms of Use

button-arrow

To enroll, check your eligibility at BrainCancerTrial.com

×